Clinical Trials


A Phase 2 Clinical Trial Evaluating AMG 714 Treatment for Vitiligo

For a complete list of clinical trials in the USA, click here.

About Vitiligo and AMG 714

  • Vitiligo is an autoimmune disorder in which some of your body’s immune cells, called T cells, attack melanocytes (the pigment producing cells in the skin). This leads to patches of skin depigmentation (loss of normal skin color). Scientists believe that specific T cells, called tissue resident memory T cells (Trm), are involved in the attack on melanocytes. Trm cells depend on the chemical signal IL-15. Therefore, scientists believe that interrupting the IL-15 signal might lead to a decrease in Trm cells, which might make vitiligo better.
  • AMG 714 is an experimental drug that interferes with IL-15 and may stop the immune system’s attack on melanocytes and allow the melanocytes to produce normal color in the skin (repigmentation).

What do participants need to know?

  • Eligible participants will be randomly assigned to one of two groups: One group will receive the study drug, AMG 714; the other group will receive an inactive substance called a placebo. 
  • This study is double-blinded, which means that during the study, neither you nor your study doctor will know who is receiving AMG 714 or placebo.
  • The treatment period is 12 weeks long, consisting of 6 clinic visits with subcutaneous doses every 2 weeks
  • The follow-up period is approximately 36 weeks, during which there are 5 clinic visits
  • During the follow-up period, participants may require Narrowband Ultraviolet B light (nbUVB) phototherapy treatment for approximately 24 weeks which will be provided at no cost
  • You will have a 2 out of 3 chance of receiving active study drug, and a 1 out of 3 chance of receiving placebo

You may be eligible to participate in the REVEAL study if you:

  • Are between the ages of 18 and 75
  • Have been diagnosed with vitiligo by a dermatologist
  • Have a noticeable amount of vitiligo both on your face and on your body
  • Are willing to stop other treatments for vitiligo

To learn more, contact the site(s) above, or visit the REVEAL website at:

Study locations and Contacts

Henry Ford Health System, Detroit, MI (PI: Iltefat Hamzavi, MD)
Contact: Angie Parks-Miller
Tel: (313) 916-0426

Contact: Jennifer Creasor
Tel: (313) 916-0427

Northwell Health, Long Island (PI: George Han, MD)
Contact: Sabah Iqbal
Tel: (516) 881-7026

Tufts Medical Center, Boston, MA (PI: Jeff Sobell, MD)
Contact: Nicole Dumont
Tel: (617) 636-7462

UC Irvine, Irvine, CA (PI: Anand Ganesan, MD)

Contact: Marcos Hurtado
Tel: (949) 824-7103

UC Davis, Davis, CA (PI: Victor Huang, MD)

Contact: John Michael Robb
Tel: (916) 551-2636

University of Massachusetts  (PI: Mehdi Rashighi, MD)
Contact: Jane Vongvirath
Tel: (508) 856-1553

Yale University, New Haven, CT (Brett King, MD)
Contact: Andrea DeClement 
Tel: (203) 785-5182